Avadel CNS v. Jazz Pharmaceuticals: Federal Circuit Reverses-in-Part & Remands
Avadel CNS Pharmaceuticals challenged Jazz Pharmaceuticals’ enforcement of seven sodium oxybate patents covering XYREM® and Avadel’s competing oxybate product. The Federal Circuit issued a split ruling — reversing some findings, vacating others, and remanding — across a 250-day appellate proceeding involving elite counsel from three major firms.
A split Federal Circuit ruling reshapes the sodium oxybate patent battleground
Avadel CNS Pharmaceuticals, LLC filed this Federal Circuit appeal on 29 August 2024, challenging rulings related to Jazz Pharmaceuticals’ portfolio of seven US patents covering sodium oxybate formulations and delivery systems — the active ingredient in XYREM®, Jazz’s flagship narcolepsy and sleep-disorder treatment. Avadel’s own extended-release sodium oxybate product directly competes in this space, making the patent boundaries commercially consequential for both parties.
The Federal Circuit closed the case on 6 May 2025 with a three-part disposition: reversed-in-part, vacated-in-part, and remanded. This means the appellate court found reversible legal error in at least some of the district-level findings, nullified certain other rulings without a final merits determination on those points, and returned the matter to the lower tribunal for further proceedings consistent with its guidance. The basis of termination also records that part of the appeal was dismissed, suggesting certain issues were resolved on procedural grounds rather than the merits.
The 250-day duration is consistent with expedited pharmaceutical patent appeals, likely reflecting the commercial urgency of the competing sodium oxybate products on the market. The precise scope of reversal and vacation — which specific patents, claims, or infringement findings were affected — is not fully determinable from the public docket summary alone, suggesting that the remand will generate further significant proceedings. The involvement of Morrison & Foerster, Latham & Watkins, and McCarter & English for Avadel, against Quinn Emanuel for Jazz, signals both parties treated this appeal as strategically critical.
Filing to Appeal Dismissed in Part in 250 days
250 days from filing to Federal Circuit decision — consistent with a complex multi-patent pharmaceutical appeal
Federal Circuit reverses-in-part: what the split ruling means for both parties
Reversed-in-part, vacated-in-part: a split appellate disposition
A Federal Circuit ruling of ‘reversed-in-part, vacated-in-part, and remanded’ is one of the most consequential appellate outcomes in patent litigation. Reversal means the court found clear legal error in specific lower-court holdings and substituted its own ruling. Vacation nullifies other holdings without a final merits determination, typically requiring the lower court to reconsider those issues. Remand sends the case back, meaning litigation continues at the trial level on the surviving and remanded issues.
Split appellate dispositionAvadel secures partial reversal — but remand means uncertainty persists
As appellant, Avadel CNS achieved a meaningful partial win: the Federal Circuit agreed that at least some lower-court rulings were legally erroneous and reversed them outright. Vacation of additional rulings also removes adverse precedent on those specific points. However, because the case is remanded, Avadel has not obtained a clean victory — further proceedings at the district level will determine the final outcome on the remanded questions, keeping commercial uncertainty alive for Avadel’s competing sodium oxybate product.
Partial appellant win, remand pendingJazz loses ground on appeal but retains a platform for the remand
Jazz Pharmaceuticals, as appellee, suffered a setback: some of the district-level rulings it defended were reversed or vacated by the Federal Circuit. This weakens Jazz’s immediate enforceability position on the affected patents or claims. However, the remand gives Jazz an opportunity to re-litigate the vacated issues before the district court, and any unreversed findings remain in place. The dismissal of part of the appeal on procedural grounds may also have preserved some favourable lower-court outcomes for Jazz.
Partial loss, remand opportunity retainedSodium oxybate market dynamics remain unsettled post-ruling
With seven patents spanning formulation, delivery, and dosing of sodium oxybate across the two competing products, the Federal Circuit’s split ruling leaves the commercial patent perimeter of XYREM® and Avadel’s extended-release product partially undefined pending remand. Pharmaceutical companies and generic/branded competitors in the CNS sleep-disorder space should treat this ruling as a signal that key claim boundaries remain actively contested. Freedom-to-operate assessments referencing these patents should be revisited in light of the reversal and vacatur.
CNS pharma patent landscape unsettledFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AVADEL CNS PHARMACEUTICALS, LLC | Company | CNS pharmaceutical company — holder of sodium oxybate formulation patents including US10966931B2Search in Eureka ↗ |
| Defendant | Jazz Pharmaceuticals, Inc. | Company | Jazz Pharmaceuticals, Inc. — maker of XYREM® sodium oxybate oral solution, defendant-appelleeSearch in Eureka ↗ |
| Plaintiff counsel | Alexander G. Siemers | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daralyn Jeannine Durie | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Gabriel K. Bell | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Herman H. Yue | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kenneth G. Schuler | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kira Alexis Davis | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Marc Nathan Zubick | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins LLP | Law Firm | Representing AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English, LLP | Law Firm | Representing AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster LLP | Law Firm | Representing AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant counsel | Ellyde R. Thompson | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Francis Dominic Cerrito | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Frank C. Calvosa | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Gabriel P. Brier | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Isaac SaidelGoley | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Quentin Jorgensen | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Quinn Emanuel Urquhart & Sullivan, LLP | Law Firm | Representing Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘REVERSED-IN-PART, VACATED-IN-PART, AND REMANDED’ — reflects a differentiated appellate review across multiple patents and legal issues. Reversal applies the de novo standard to questions of law (claim construction, eligibility) and the clear error standard to factual findings, indicating the court identified at least one legally erroneous holding it could resolve finally. Vacation, by contrast, typically signals the court found procedural or evidentiary deficiency requiring the lower court’s re-examination rather than a direct appellate correction. The partial appeal dismissal further narrows the issues surviving for remand.
US10966931B2 and six further sodium oxybate patents in suit
The seven patents in suit — led by US10966931B2 (application US17/012831) — collectively cover sodium oxybate in its formulated, dosed, and delivered forms for treating CNS sleep disorders including narcolepsy. Sodium oxybate (gamma-hydroxybutyrate, GHB) requires specialised pharmaceutical engineering to achieve controlled and extended release, and the patent family reflects years of formulation and delivery innovation anchored by application filings ranging from the early 2010s through the early 2020s. The portfolio spans both product composition and method-of-use claims.
For the CNS pharmaceutical sector, a portfolio of this breadth over a single active ingredient signals a classic ‘patent thicket’ strategy intended to create overlapping barriers around a commercially dominant product. XYREM® has generated billions in annual revenue for Jazz, and the asserted patents represent the legal perimeter Jazz has constructed around that franchise. Avadel’s challenge — and the Federal Circuit’s partial reversal — suggests that at least some of those barriers may not have been constructed on legally durable ground, which has direct implications for other sodium oxybate competitors and for CNS drug developers seeking to enter adjacent therapeutic categories.
Should you run an FTO against US10966931B2 and the sodium oxybate portfolio?
Any pharmaceutical company developing, manufacturing, or commercialising sodium oxybate formulations — including extended-release or modified-release CNS products — should treat this seven-patent portfolio as a live FTO concern. The Federal Circuit’s split ruling means the enforceability perimeter of these patents is actively shifting: some claims may have been reversed into non-infringement or invalidity, while others remain viable pending remand. A pre-launch or pre-NDA FTO that pre-dates this ruling may now be materially inaccurate.
PatSnap Eureka’s FTO Search Agent can rapidly map each of the seven asserted patents against your product’s formulation and delivery parameters, flag which claims survived the Federal Circuit ruling, and surface any post-remand prosecution or reissue activity. Eureka’s citation and family analysis also identifies continuation risk — whether Jazz has filed continuation applications that could extend the effective patent term of the reversed or vacated claims into new claim constructions.
Run a freedom-to-operate analysis on US10966931B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit sodium oxybate and CNS pharmaceutical patent appeals
Cases involving Federal Circuit appeals over sodium oxybate, CNS pharmaceutical formulations, and REMS-tied patent portfolios most relevant to this dispute.
What this case signals for the CNS pharmaceutical IP landscape
A multi-patent Federal Circuit split ruling in a branded sodium oxybate dispute carries broad lessons for CNS pharma IP strategy and competitor positioning.
Multi-patent portfolios invite split Federal Circuit dispositions
When seven patents span a single product area, appellate courts routinely issue differentiated holdings across claims and patents — reversing some, vacating others, dismissing still others. Companies asserting or defending large CNS pharmaceutical portfolios should anticipate non-uniform appellate outcomes and structure trial-level records to preserve distinct arguments for each patent family.
Remand resets the commercial clock for competing sodium oxybate products
The remand to the district court means neither party has a judicially final resolution on the full patent dispute. Avadel’s competing product remains exposed to further infringement findings on remanded issues, while Jazz’s exclusivity position on XYREM® remains partially challenged. Product teams and licensing negotiators should monitor the remand proceedings closely before drawing FTO conclusions.
AVADEL v Jazz — key questions answered
The Federal Circuit issued a split ruling: reversed-in-part, vacated-in-part, and remanded. This means the court found reversible legal error in some lower-court holdings, nullified other rulings without final merits resolution, and returned the case to the district court for further proceedings. Part of the appeal was also dismissed on procedural grounds.
Seven US patents were in suit: US10966931B2, US11147782B1, US8731963B1, US10758488B2, US10959956B2, US11077079B1, and US10813885B1. All relate to sodium oxybate formulations, dosing systems, and delivery methods covering both Jazz’s XYREM® oral solution and Avadel’s competing extended-release sodium oxybate product.
Reversal means the appellate court found clear legal error in specific lower-court holdings and substituted its own ruling on those points. Vacation nullifies other holdings — typically where procedural or evidentiary issues require the lower court to reconsider rather than the Federal Circuit to decide. Remand returns the surviving and vacated issues to the district court for further proceedings consistent with the appellate guidance.
The ruling leaves the patent perimeter of both XYREM® and Avadel’s extended-release product partially undefined pending remand. Some Jazz patent claims may have been reversed into non-enforceability, potentially easing market access for competitors. However, the remand means litigation continues, and neither party has a judicially final resolution. Companies conducting FTO analyses on sodium oxybate products should update those analyses to reflect the split ruling.
The basis of termination records ‘Appeal Dismissed in Part,’ which typically indicates that certain issues raised on appeal were resolved without merits adjudication — for example, due to lack of appellate standing, mootness, or failure to preserve the issue at trial. The public docket summary does not specify which portions were dismissed or on what precise procedural basis, so this remains uncertain from the available record.
PatSnap Eureka searches patents and litigation data to answer instantly.